LOG IN

Real-World Quality of Life and How it Relates to Overall Survival in Metastatic Colorectal Cancer: Results from the PROMETCO Study

Data presented at the ESMO GI Congress 2026

Andrey Mitroshkin,1 Jean-Baptiste Bachet,2 Rocio Garcia-Carbonero,3 Carmine Pinto,4 György Bodoky,5 Francesca Marti Marti,6 Bénédicte Chevallier,7 Elias Choucair,7 Adam Sullivan,8 Miriam Koopman.9

1Klinikum Freudenstadt, Akademisches Lehrkrankenhaus der Universität Tübingen, Freudenstadt, Germany; 2Sorbonne Université, Service d’Hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France; 3Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; 4Medical Oncology, Comprehensive Cancer Centre, AUSL – IRCCS di Reggio Emilia, Reggio Emilia, Italy; 5Department of Medical Oncology, Dél-Pesti Centrumkórház Szent László Telephely Albert Flórián, Budapest, Hungary; 6Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; 7Servier, Servier Affaires Medicales, Suresnes, France; 8Servier, Servier Pharmaceuticals, Boston, United States of America; 9Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.

PROMETCO: Study background and aim

  • A growing range of later-line therapies for mCRC, such as FTD/TPI ± bevacizumab, has prolonged survival in clinical trial settings1,2

  • However, real-world studies of mCRC treatment in 3L and beyond have been limited to specific agents or to a single country, and provide little information on real-world QoL outcomes and their association with survival3,4

  • PROMETCO (NCT03935763) is an international, prospective, real-world study investigating outcomes, including QoL, in patients with mCRC after two disease progressions since diagnosis. Its prospective design strengthens the collection of robust QoL data, offering high-quality evidence in a real-world setting

Aim: To assess real-world QoL and its impact on mOS from 1L in patients with mCRC

Inclusion criteria:5

  • Adults (aged ≥18 years) with a confirmed mCRC diagnosis

  • Two disease progressions since diagnosis of first metastasis

  • Willing to receive subsequent treatment

The study consisted of retrospective medical chart data collection and a prospective observational period post inclusion. Patients were followed up regularly, with no fixed schedule, for 18 months or until death5

Clinician-reported QoL was assessed using ECOG PS, and patient-reported QoL was assessed via EQ-5D-5L VAS at baseline until end of follow-up or death

Baseline characteristics

QoL outcomes

Impact of QoL on OS

Conclusions

1L, first-line; 3L, third-line; ECOG PS, Eastern Cooperative Oncology Group performance status; EQ-5D-5L VAS, EuroQol 5-Dimension 5-Level visual analogue scale; FTD/TPI, trifluridine/tipiracil; mCRC, metastatic colorectal cancer; mOS, median overall survival; QoL, quality of life.
1. Prager GW, et al. N Engl J Med. 2023;388(18):1657–67; 2. Dasari A, et al. Lancet. 2023;402(10395):41–53; 3. Taieb J, et al. BMC Cancer. 2023;23(1):94; 4. Weiss L, et al. ESMO Open. 2022;7(1):100391; 5. Koopman M, et al. ESMO Gastrointest Oncol. 2025;9:100214.

back to top

 

back to top